Outlook Therapeutics (OTLK) Equity Income (2021 - 2026)
Outlook Therapeutics' (OTLK) quarterly Equity Income came in at -$41013.0 in Q2 2026, down 32.8% year-over-year from -$61028.5 in Q2 2025, and up 9.1% quarter-over-quarter from -$45119.0 in Q1 2026.
Powered by 
Analysis
Outlook Therapeutics (OTLK) Equity Income (2021 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Equity Income for 6 consecutive years, with -$41013.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Equity Income fell 32.8% year-over-year to -$41013.0 in Q2 2026; TTM through Jun 2026 was -$165185.0, a 42.66% decrease from a year earlier, with the FY2025 full-year figure at -$141007.0, down 39.97% from the prior year.
- Equity Income was -$41013.0 for Q2 2026 at Outlook Therapeutics, up from -$45119.0 in the prior quarter.
- Over five years, Equity Income peaked at $21505.0 in Q4 2022 and troughed at -$57497.0 in Q2 2024.
- A 5-year average of -$22366.0 and a median of -$23780.0 in 2023 frame the typical range for Equity Income.
- Across the five-year window, Equity Income soared 190.91% in 2022 and plunged 1406.71% in 2024, its largest moves.
- Over 5 years, Equity Income stood at $21505.0 in 2022, then sank by 88.15% to $2548.0 in 2023, then sank by 1406.71% to -$33295.0 in 2024, then slipped by 16.04% to -$38634.0 in 2025, then decreased by 6.16% to -$41013.0 in 2026.
- The last three Equity Income figures came in at -$41013.0 (Q2 2026), -$45119.0 (Q1 2026), and -$38634.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Outlook Therapeutics | 88.06 Mn | 76.82 Mn | -8,265.00 | -41,013.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41,013.00 |
| Mar 31, 2026 | -45,119.00 |
| Dec 31, 2025 | -38,634.00 |
| Sep 30, 2025 | -40,419.00 |
| Jun 30, 2025 | -30,884.00 |
| Mar 31, 2025 | -36,409.00 |
| Dec 31, 2024 | -33,295.00 |
| Sep 30, 2024 | -15,198.00 |
| Jun 30, 2024 | -57,497.00 |
| Mar 31, 2024 | -30,595.00 |
| Dec 31, 2023 | 2,548.00 |
| Sep 30, 2023 | -8,350.00 |
| Jun 30, 2023 | -7,188.00 |
| Mar 31, 2023 | -16,965.00 |
| Dec 31, 2022 | 21,505.00 |
| Sep 30, 2022 | -7,226.00 |
| Jun 30, 2022 | -11,805.00 |
| Mar 31, 2022 | -6,044.00 |
| Dec 31, 2021 | -23,655.00 |
| Sep 30, 2021 | 389,006.00 |